Leonard Zehr, Author at BioTuesdays

Feature

Aligos Therapeutics targeting functionally curative HBV regimen

Even though a number of antiviral medications are in use to treat chronic hepatitis B virus (HBV) infections, Aligos Therapeutics (NASDAQ:ALGS) is going one step further with a portfolio of drug candidates in clinical...

October 19, 2021

Feature

Acasti Pharma transitions to orphan diseases from cardiovascular

After a failed Phase 3 trial in August 2020 with its CaPre lead drug candidate for patients with severe hypertriglyceridemia, Acasti Pharma (NASDAQ, TSXV:ACST) has transitioned into the rare and orphan disease sector...

October 12, 2021

Feature

ContraFect advancing new modality for antibiotic-resistant infections

In a bid to counter the next great health crisis, ContraFect (NASDAQ:CFRX) is in late-stage development of a new modality to treat life-threatening and antibiotic-resistant infections, using direct lytic agents (DLAs).

October 5, 2021

Feature

Aptevo Therapeutics oncology pipeline offers multiple shots on goal

Aptevo Therapeutics (NASDAQ:APVO) has developed a broad portfolio of potential immuno-oncology therapies with multiple mechanisms of action from two differentiated bispecific and multi-specific antibody platform...

September 28, 2021

Feature

ReShape Lifesciences forging weight loss and metabolic health solutions

With an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease, ReShape Lifesciences (NASDAQ:RSLS) is reshaping patients minds, bodies and lives.

September 21, 2021

Feature

UNITY Biotechnology developing therapeutics to slow, halt or reverse diseases of aging

UNITY Biotechnology’s (NASDAQ:UBX) current focus is on developing medicines to selectively eliminate or modulate senescent cells and to provide transformative benefit in age-related ophthalmologic and neurologic...

September 14, 2021

Feature

Bombi Biomics fighting superbugs with amphibian-derived anti-microbial peptides

Closely-held Bombi Biomics of the Netherlands has developed a technology known as Bombilysin with the potential to kill bacteria from the outside shell in contrast to conventional antibiotics that typically are intended...

August 31, 2021

Developments

iBio acquires exclusive rights to develop anti-CD25 antibody RTX-003 from RubrYc

iBio (NYSEA:IBIO) bolstered its immuno-oncology pipeline with the acquisition of exclusive rights to develop and commercialize the anti-CD25 monoclonal antibody, RTX-003, from RubrYc. The partnership also includes an...

August 25, 2021

Feature

Anebulo Pharma addressing cannabinoid intoxication as legalization grows

Anebulo Pharmaceuticals (NASDAQ:ANEB) is developing a novel antidote for cannabinoid intoxication and, longer term, other indications related to abuse and addiction.

August 24, 2021

Feature

Lucid Psycheceuticals focusing on Total Brain Health

Lucid Psycheceuticals’ next generation approach to total brain health is targeting the interface between mental health and neurodegenerative disorders with therapeutic products inspired by psychedelics and new chemical...

August 17, 2021

Author - Leonard Zehr

Aligos Therapeutics targeting functionally curative HBV regimen

Acasti Pharma transitions to orphan diseases from cardiovascular

ContraFect advancing new modality for antibiotic-resistant infections

Aptevo Therapeutics oncology pipeline offers multiple shots on goal

ReShape Lifesciences forging weight loss and metabolic health solutions

UNITY Biotechnology developing therapeutics to slow, halt or reverse diseases of aging

Bombi Biomics fighting superbugs with amphibian-derived anti-microbial peptides

iBio acquires exclusive rights to develop anti-CD25 antibody RTX-003 from RubrYc

Anebulo Pharma addressing cannabinoid intoxication as legalization grows

Lucid Psycheceuticals focusing on Total Brain Health

General

More